Cancer Res Treat.  2004 Oct;36(5):298-302.

Prognostic Significance of CD24 Expression in Gastric Carcinoma

• Darwish NS
• Kim MA
• Chang MS
• Lee HS
• Lee BL
• Kim YI
• Kim WH

Abstract

PURPOSE
The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in hematological malignancies, as well as in a large variety of solid tumors. Its expression is now known to be related to the prognosis of several kinds of tumors. This study is designed to examine the prognostic significance of CD24 in Korean gastric cancer patients. MATERIALS AND METHODS: In the present study, we examined CD24 expression in 300 consecutive cases of gastric carcinoma by immunohistochemical staining using the tissue-array method. We also investigated the clinicopathological profiles related to CD24 expression. RESULTS: One hundred and three cases out of 300 (34.3%) showed the positive expression of CD24. The altered expression of CD24 was significantly associated with differentiated cancer (p=0.003), the intestinal subtype according to the Lauren classification (p<0.001), the advanced stage cancer (p=0.027), with lymphatic invasion (p=0.038) and with vascular invasion (p=0.006). The survival analysis revealed that the patients with CD24 positive expression showed significantly poorer survival than those without CD24 expression. Moreover, a combined evaluation revealed that PTEN /CD24 cases showed the best survival compared to other groups (p=0.01). CONCLUSION: Positive CD24 expression occurs in a subset of gastric carcinomas and it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival.

Keyword

Immunohistochemistry; Survival analysis; Stomach neoplasms

MeSH Terms

Antigens, CD24
Blood Vessels
Classification
Hematologic Neoplasms
Humans
Immunohistochemistry
Prognosis
Stomach Neoplasms
Survival Analysis
Antigens, CD24

Figure

• 

  Fig. 1 Microscopic features of CD24 immunohistochemistry. The gastric carcinomas were analyzed using the tissue array method (A, ×1). Non-neoplastic gastric mucosa did not express CD24 (B, ×200). A gastric cancer with intense membraneous and cytoplasmic staining of CD24 (C, ×200). A case with negative CD24 expression in cancer cells (D, ×200).

• 

  Fig. 2 Survival curves using the Kaplan-Meier method. A. Survival analysis showed that CD24 positive tumors have an unfavorable prognosis compared to CD24 negative carcinomas (p=0.02). B. Survival analysis according to the expression of two proteins. The patients with PTEN+ and CD24- expression pattern showed the best outcome (p=0.0003).

Reference

1. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P. CD24, a mucin- type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood. 1997; 89:3385–3395. PMID: 9129046.

2. Kay R, Rosten PM, Humphries RK. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol. 1991; 147:1412–1416. PMID: 1831224.

3. Akashi T, Shirasawa T, Hirokawa K. Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch. 1994; 425:399–406. PMID: 7820302.

4. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002; 161:1215–1221. PMID: 12368195.

5. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P, Sthoeger ZM. CD24 is a marker for human breast carcinoma. Cancer Lett. 1999; 143:87–94. PMID: 10465342.

6. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate. 2004; 58:183–192. PMID: 14716744.

7. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003; 200:39–46. PMID: 12692839.

8. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001; 92:1427–1434. PMID: 11745219.

9. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 2001; 61:1569–1577. PMID: 11245467.

10. Ilangumaran S, He HT, Hoessli DC. Microdomains in lymphocyte signalling: beyond GPI-anchored proteins. Immunol Today. 2000; 21:2–7. PMID: 10637551.

11. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol. 2001; 166:5567–5577. PMID: 11313396.

12. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000; 60:6714–6722. PMID: 11118057.

13. Kanai Y, Hirohashi S. Sugimura T, Sasako M, editors. Invasion and metastasis. Gastric Cancer. 1997. Oxford: Oxford University Press;p. 109–123.

14. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. 1998; 12:1241–1251. PMID: 9737727.

15. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998; 95:9325–9330. PMID: 9689079.

16. Roux P. PTEN: a tumor suppressor with original properties. Bull Cancer. 1999; 86:522–525. PMID: 10417424.

17. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002; 82:285–291. PMID: 11896207.